Anifrolumab in Refractory Dermatomyositis and Antisynthetase Syndrome.
Ryan Bonaventure Soares, Jihad Ben Gabr, Mark Ash...
https://pubmed.ncbi.nlm.nih.gov/40297385/Actively Recruiting
Led by AstraZeneca · Updated on 2026-09-24
240
Participants Needed
237
Research Sites
65 weeks
Total Duration
Researchers are evaluating the safety and effectiveness of subcutaneous anifrolumab injections compared to placebo in adults with moderate to severe Idiopathic Inflammatory Myopathies IIM, including polymyositis PM and dermatomyositis DM. This Phase III, multicenter, randomized, placebo-controlled, and double-blind study adds anifrolumab or placebo to participants standard of care treatment to assess overall disease activity. Participants receive either anifrolumab or a matched placebo by subcutaneous injection once weekly for 52 weeks while continuing their standard treatments. After this period, all participants have the option to receive open-label anifrolumab weekly for an additional 52 weeks. This design allows researchers to compare the effects of anifrolumab against placebo and then observe longer-term effects when all receive anifrolumab. Throughout the study, participants undergo regular assessments including the Total Improvement Score TIS at 52 weeks as the main outcome. Additional evaluations include muscle strength testing, corticosteroid dosage monitoring, skin disease activity, and itch severity up to 52 weeks. Safety and disease activity improvements for both PM and DM participants are closely monitored. The study lasts up to approximately two years, including both blinded and open-label treatment phases.
CONDITIONS
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
A
AstraZeneca Clinical Study Information Center
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
AstraZeneca
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Anifrolumab + standard‑of‑care | Placebo + standard‑of‑care | Standard care (no anifrolumab) |
|---|---|---|---|
| What it is | Anifrolumab, a type I interferon receptor antibody, given as weekly subcutaneous injections along with standard immunosuppressive therapy | Matching placebo injections given weekly in addition to standard immunosuppressive therapy | Standard care consists of corticosteroids and immunosuppressants such as methotrexate, azathioprine or IVIG for moderate to severe disease |
| Role in trial | Experimental intervention being evaluated for efficacy and safety | Control comparator receiving placebo to match investigational treatment | Not part of the trial but reflects usual treatment context |
| Primary use | To evaluate whether adding anifrolumab to standard therapy improves disease activity in PM/DM | To serve as a control for comparison against anifrolumab plus standard therapy | Represents current treatment available to most eligible patients not receiving anifrolumab |
| How it is given or performed | Subcutaneous anifrolumab injection once weekly for 52 weeks alongside existing immunosuppressive drugs | Subcutaneous placebo injection once weekly for 52 weeks on top of standard medications | Typical immunosuppressive treatments given per clinician choice; may include corticosteroids, methotrexate, azathioprine or IVIG schedules |
| Evidence status | No published trial results yet; efficacy under investigation in phase III trial | Used as control; not expected to improve beyond standard therapy alone | Considered effective to induce and maintain remission in many cases; experience based on smaller studies and expert guidelines |
| Important risks | Risks not yet fully characterized in this population; safety being assessed in the trial | Placebo injections are generally safe; risks mainly from background therapy | Immunosuppressants and steroids can increase infection risk and have long‑term side effects |
| Important limitations | No peer‑reviewed efficacy data yet; trial results pending | Placebo does not reflect active treatment beyond standard care | Evidence is based on consensus or small studies, not large randomized comparisons |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 52 weeks
Participants receive weekly subcutaneous injections of either anifrolumab or placebo alongside their standard care for 52 weeks.
Weekly visits
Duration - 52 weeks
All participants receive open-label anifrolumab injections once weekly for an additional 52 weeks.
Weekly visits
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Ryan Bonaventure Soares, Jihad Ben Gabr, Mark Ash...
https://pubmed.ncbi.nlm.nih.gov/40297385/AstraZeneca
Lead Sponsor